Abstract
Drug-induced hypersensitivity is an adverse reaction, characterised by damaging immune-mediated responses, initiated by medicine given at therapeutic doses for prevention, diagnosis or treatment. Immune-mediated drug hypersensitivity accounts for 6–10% of the adverse drug reactions, which rank between the fourth and sixth leading causes of death in the US. With <10% of all adverse drug reactions reported, the magnitude of the problem is significant, with estimates of costs >$US30 billion annually in the US (1995 value). In addition, the costs of not determining the potential of a drug to produce hypersensitivity in the pre-clinical phase of drug development can be substantial. It has been estimated that the pre-clinical phase and clinical phase I, phase II and phase III costs are approximately $US6 million, $US12 million, $US12 million and $US100 million per drug, respectively (1999 values). It is important that investigational drugs with the potential to produce hypersensitivity reactions be identified as early in the development process as possible. Some adverse reactions to drugs can be avoided if drug-drug interactions are known or if there is a structure-activity relationship established. However, these methods are inadequate. Appropriate animal models of drug-induced hypersensitivity are needed, especially because hypersensitivity has been cited as the leading reason for taking drugs off the market.
It is of critical importance to be able to predict hypersensitivity reactions to drugs. Most anaphylactic reactions occur in atopic individuals. Similarly, patients who have experienced other hypersensitivity reactions are more likely to have recurrent reactions. Therefore, animal models should be considered that predispose the animal to the reaction, such as the use of appropriate adjuvants and species. Using known positive controls of varying strengths, the investigator can rank the reaction against the positive controls as standards. This approach might yield greater results in a shorter period of time than using novel models. For the greatest safety, use of well understood models that have been thoroughly validated is imperative.
Similar content being viewed by others
Notes
The use of trade names is for product identification purposes only and does not imply endorsement.
This is the highest FDA warning based on serious safety issues discovered during post-marketing surveillance, so-named because the warning information is conspicuously circumscribed by a black box.
References
World Health Organization. International drug monitoring: the role of the hospital. Geneva: World Health Organization, 1966
Coombs RRA, Gell PGH. Classification of allergic reactions responsible for clinical hypersensitivity and disease. In: Gell PGH, Coombs RRA, editors. Clinical aspects of immunology. 2nd ed. Oxford: Blackwell Scientific Publications, 1968: 575–96
Naisbitt DJ, Gordon SF, Pirmohamed M, et al. Immunological principles of adverse drug reactions: the initiation and propagation of immune responses elicited by drug treatment. Drug Saf 2000; 23: 483–507
Ioannidis JPA, Lau J. Completeness of safety reporting in randomized trials. JAMA 2001; 285: 437–43
Brewer T, Colditz GA. Postmarketing surveillance and adverse drug reactions: current perspectives and future needs. JAMA 1999; 281: 824–9
Bates DW. Drugs and adverse drug reactions: how worried should we be? JAMA 1998; 279: 1216–7
Johnson JA, Bootman JL. Drug-related morbidity and mortality: a cost-of-illness model. Arch Intern Med 1995; 155: 1949–56
Adkinson Jr NF, Essayan D, Gruchalla R, et al. Task force report: future research needs for the prevention and management of immune-mediated drug hypersensitivity reactions. J Allergy Clin Immunol 2002; 109: S461
Wood AJJ. Thrombotic thrombocytopenic purpura and clopidogrel: a need for new approaches to drug safety. N Engl J Med 2000; 342: 1824–6
Lasser KE, Allen PD, Woolhandler SJ, et al. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002; 287: 2215–20
Neugut AI, Ghatak AT, Miller RL. Anaphylaxis in the United States: an investigation into its epidemiology. Arch Intern Med 2001; 161: 15–21
Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279: 1200–5
Payne MP, Walsh PT. Structure-activity relationships for skin sensitization potential: development of structural alerts for use in knowledge-based toxicity prediction systems. J Chem Inf Comput Sci 1994; 34: 154–61
Karol MH, Graham C, Gealy R, et al. Structure-activity relationships and computer-assisted analysis of respiratory sensitization potential. Toxicol Lett 1996; 86: 187–91
Pease CK, Basketter DA, Patlewicz GY. Contact allergy: the role of skin chemistry and metabolism. Clin Exp Dermatol 2003; 28: 177–83
Olson H, Betton G, Robinson D, et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Reg Toxicol Pharmacol 2000; 32: 56–67
Uetrecht JP. The role of leukocyte-generated reactive metabolites in the pathogenesis of idiosyncratic drug reactions. Drug Metab Rev 1992; 24: 299–366
Tizard IR, editor. Immunology. 2nd ed. Philadelphia (PA): Saunders College Publishing, 1988: 455–529
Golub ES, Green DR. Immunology: a synthesis. 2nd ed. Sunderland (MA): Sinauer Associates Inc., 1991: 596–642
Ahlstedt S. Penicillin allergy: can the incidence be reduced. Allergy 1984; 39: 151–64
Tizard IR, editor. Immunology. 2nd ed. Philadelphia (PA): Saunders College Publishing, 1988: 18–24
Park BK, Pirmohamed M, Kitteringham NR. Role of drug disposition in drug hypersensitivity: a chemical, molecular, and clinical perspective. Chem Res Toxicol 1998; 11: 969–88
Griem P, Wulferink M, Sachs B, et al. Allergic and autoimmune reactions to xenobiotics: how do they arise? Immunol Today 1998; 19: 133–41
Parkinson A. Biotransformation of xenobiotics. In: Klaassen CD, editor. Casaratt and Doull’s Toxicology: the basic science of poisons. 5th ed. New York: McGraw Hill, 1996: 113–86
Schnyder B, Mauri-Hellweg D, Zanni M, et al. Direct, MHC-dependent presentation of the drug sulfamethoxazole to human T-cell clones. J Clin Invest 1997; 100: 136–41
Pichler WJ. Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept. Curr Opin Allergy Clin Immunol 2002; 2: 301–5
Gruchalla RS. Drug allergy. J Allergy Clin Immunol 2003; 111: S548
Kemp SF, Lockey RF, Wolf BL, et al. Anaphylaxis: a review of 266 cases. Arch Intern Med 1995; 155: 1749–54
Suzuki Y, Inaga R, Aono T, et al. Human herpesvirus 6 infection as a risk factor for the development of severe drug-induced hypersensitivity syndrome. Arch Dermatol 1996; 134: 1108–12
Antonen JA, Markula KP, Pertovaara MI, et al. Adverse drug reactions in Sjogren syndrome: frequent allergic reactions and a specific trimethoprim-associated systemic reaction. Scand J Rheumatol 1999; 28: 157–9
Matzinger P. An innate sense of danger. Semin Immunol 1998; 10: 399–415
Golub ES, Green DR. Immunology: a synthesis. 2nd ed. Sunderland (MA): Sinauer Associates Inc., 1991: 535
Albers R, van der Pijl A, Bol M, et al. Stress proteins (HSP) and chemical-induced autoimmunity. Toxicol Appl Pharmacol 1996; 140: 70–6
Benoit Y, Chadenson O, Ducloux B, et al. Hypersensitivity to Althesin infusion: measurement of complement involvement. Anaesthesia 1983; 38: 1079–81
Rosnow CE, Moss J, Philbin DM, et al. Histamine release during morphine and fentanyl anaesthesia. Anesthesiology 1982; 56: 93–6
Manning ME, Stevenson DD. Pseudo-allergic drug reactions: aspirin, nonsteroidal anti-inflammatory drugs, dyes, additives and preservatives. Immunol Allergy Clin North Am 1991; 11: 659–78
Furst SM, Gandolfi AJ. Interaction of lymphocytes with Kupffer cells from halothane-exposed guinea pigs. Int Arch Allergy Immunol 1997; 114: 46–53
Furst SM, Luedke D, Gaw HH, et al. Demonstration of a cellular immune response in halothane-exposed guinea pigs. Toxicol Appl Pharmacol 1997; 143: 245–55
Zimmerman HJ, Lewis JH, Ishak KG, et al. Ticrynafen-associated hepatic injury: analysis of 340 cases. Hepatology 1984; 4: 315–23
Breen EG, McNicholl J, Cosgrove E, et al. Fatal hepatitis associated with diclofenac. Gut 1986; 27: 1390–3
Richerson HB, Seidenfeld JJ, Ratajczak HV, et al. Chronic experimental interstitial pneumonitis in the rabbit. Am Rev Respir Dis 1978; 117: 5–13
Naldi L, Conforti A, Venegoni M, et al. Cutaneous reactions to drugs: an analysis of spontaneous reports in four Italian regions. Br J Clin Pharmacol 1999; 48: 839–46
Bigby M, Jick S, Jick H, et al. Drug-induced cutaneous reactions: a report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA 1986; 256: 3358–63
Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333: 1600–7
Ahlstdet S, Edstrom B, Svard PO, et al. New aspects on antigens in penicillin allergy. Crit Rev Toxicol 1980; 7: 219–77
Pichler W, Yavalkar N, Schmid S, et al. Pathogenesis of drug-induced exanthems. Allergy 2002; 57: 884–93
Sarlo K, Clark ED. A tier approach for evaluating the respiratory allergenicity of low molecular weight chemicals. Fundam Appl Toxicol 1992; 18: 107–14
Calabrese EJ. Suitability of animal models for predictive toxicology: theoretical and practical considerations. Drug Metab Rev 1984; 15: 505–23
Garattini S. Toxic effects of chemicals: difficulties in extrapolating data from animals to man. Ann Rev Toxicol 1985; 16: 1–29
Ratajczak HV, Lange RW, Sothern RB, et al. Surgical influence on murine immunity and tumor growth: relationship of body temperature and hormones with splenocytes [published erratum appears in Proc Soc Exp Biol Med 1992; 200: 448–51]. Proc Soc Exp Biol Med 1992; 199: 432–40
Sothern RB, Roitman-Johnson B. Biological rhythms and immune function. In: Ader R, Feiten DL, Cohen N, editors. Psychoneuroimmunology. 3rd ed. San Diego (CA): Academic Press, 2001: 1, 445–79
Maestroni GJM, Conti A, Pierpaoli W. Role of the pineal gland in immunity. J Neuroimmunol 1986; 13: 19–30
Sanchez de la Pena S. The feedsideward of cephalo-adrenal immune interactions. Chronobiologia 1993; 20: 1–52
Zbinden G. Predictive value of animal studies in toxicology. Reg Toxicol Pharmacol 1991; 14: 167–77
Verdier F, Chazal I, Descotes J. Anaphylaxis models in the guinea-pig. Toxicology 1994; 93: 55–61
Landsteiner K, Jacobs J. Studies on the sensitization of animals with simple chemical compounds. J Exp Med 1935; 61: 643–57
Wierda D, Smith HW, Zwickl CM. Immunogenicity of biopharmaceuticals in laboratory animals. Toxicology 2001; 158: 71–4
Vial T, Descotes J. Contact sensitization assays in guinea-pigs: are they predictive of the potential for systemic allergic reactions? Toxicology 1994; 93: 63–75
Weaver JL, Staten D, Hastings KL. An evaluation of guinea pig hypersensitivity test for ability to detect systemic hypersensitivity potential of drugs [abstract]. Toxicologist 1999; 48: 316
Albers R, Breeders A, van Der Pijl A, et al. The use of reporter antigens in the popliteal lymph node assay to assess immunomodulation by chemicals. Toxicol Appl Pharmacol 1997; 143: 102–9
Hastings KL. Pre-clinical methods for detecting the hypersensitivity potential of Pharmaceuticals: regulatory considerations. Toxicology 2001; 158: 85–9
Austen KF, Humphrey JH. In vitro studies of the mechanism of anaphylaxis. In: Dixon Jr JH, Humphrey JH, editors. Advances in immunology. New York: Academic Press, 1963: 1–96
Davis BD, Dulbecco R, Eisen HN, et al., editors. Microbiology. 2nd ed. New York: Harper and Row, 1973: 539
Coenen TMM, Ratajczak HV. Equal allergenic potency of beta-lactam antibiotics produced by chemical or enzymatic manufacturing: mouse IgE test. Int Arch Allergy Immunol 2001; 126: 173–8
Mota I, Wong D. Homologous and heterologous passive cutaneous anaphylactic activity of mouse antisera during the course of immunization. Life Sci 1969; 8: 813–20
Kimber I, Hilton J, Basketter DA, et al. Predictive testing for respiratory sensitization in the mouse. Toxicol Lett 1996; 86: 193–8
Hilton J, Dearman RJ, Boylett MS, et al. The mouse IgE test for the identification of potential chemical respiratory allergens: considerations of stability and controls. J Appl Toxicol 1996; 16: 165–70
Dearman RJ, Skinner RA, Humphreys NE, et al. Methods for the identification of chemical respiratory allergens in rodents: comparisons of cytokine profiling with induced changes in serum IgE. J Appl Toxicol 2003; 23: 199–207
Dearman RJ, Kimber I. Cytokine fingerprinting and hazard assessment of chemical respiratory allergy. J Appl Toxicol 2001; 21: 153–63
Ritz HL, Evans BLB, Bruce RD, et al. Respiratory and immunological responses of guinea pigs to enzyme containing detergents: a comparison of intratracheal and inhalation modes of exposure. Fundam Appl Toxicol 1993; 21: 31–7
Kawabata TT, Babcock LS, Gauggel DL, et al. Optimization and validation of an ELISA to measure specific guinea pig IgG1 antibody as an alternative to the in vivo passive cutaneous anaphylaxis assay. Fundam Appl Toxicol 1995; 24: 238–46
Regel JF, Klos A. Minor role of the C3a receptor in systemic anaphylaxis in the guinea pig. Immunopharmacology 2000; 46: 15–28
Descotes J, Verdier F. Popliteal lymph node assay. In: Burleson GR, Dean JH, Munson AE, editors. Methods in immunotoxicology. New York: Wiley-Liss, 1995; 1: 189–96
Buehler EV. Prospective testing for delayed contact hypersensitivity in guinea pigs: the Buehler method. In: Burleson GR, Dean JH, Munson AE, editors. Methods in immunotoxicology. New York: Wiley-Liss, 1995; 2: 343–56
Magnusson B, Kligman AM. The identification of contact allergens by animal assay. The guinea pig maximization test. J Invest Dermatol 1969; 52: 268–76
Draize JH, Woodard G, Calvery HO. Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J Pharmacol Exp Ther 1944; 82: 337–90
Kimber I. The local lymph node assay. In: Burleson GR, Dean JH, Munson AE, editors. Methods in immunotoxicology. New York: Wiley-Liss, 1995: 279–90
Gad SC, Dunn BJ, Dobbs DW, et al. Development and validation of an alternative dermal sensitization test: the mouse ear swelling test (MEST). Toxicol Appl Pharmacol 1986; 84: 93–114
Descotes J. Identification of contact allergens: the mouse ear sensitization assay. J Toxicol Cutaneous Ocul Toxicol 1988; 7: 263–72
Basketter DA, Scholes EW, Chamberlain M, et al. An alternative strategy to the use of guinea pigs for the identification of skin sensitization hazard. Food Chem Toxicol 1995; 33: 1051–6
Friedman MA, Woodcock J, Lumpkin MM, et al. The safety of newly approved medicines: do recent market removals mean there is a problem? JAMA 1999; 281: 1728–34
Irey NS. When is a disease drug induced? In: Riddell RH, editor. Pathology of drug-induced and toxic diseases. New York: Churchill Livingstone, 1982: 1–18
Gradle C, Ratajczak H, Fresco R, et al. Definition of the pulmonary antibody response to ovalbumin following local challenge in systemically immunized rats. Proc Soc Exp Biol Med 1988; 188: 61–9
Ratajczak HV, Richards DW, Richerson HB. Systemic and local lymphocyte responses in experimental hypersensitivity pneumonitis. Am Rev Respir Dis 1980; 122: 761–8
Acknowledgements
The author thanks Drs D. Juras and J. Siegel for their constructive criticism of this manuscript. No sources of funding were used to assist in the preparation of this review. The author has no conflicts of interest that are directly relevant to the content of this review.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ratajczak, H.V. Drug-Induced Hypersensitivity. Toxicol Rev 23, 265–280 (2004). https://doi.org/10.2165/00139709-200423040-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00139709-200423040-00006